Next-Gen ADCs Driving ‘Renaissance’ in Already Hot Oncology Drug Class

ADC Therapeutics, Sutro Biopharma and Zai Lab are among those developing antibody-drug conjugates to address payload and toxicity challenges of current ADCs—and rapidly grow the multi-billion-dollar market.

Scroll to Top